Ladenburg analyst Wangzhi Li raised the firm's price target on Arcturus Therapeutics to $28 from $22 and keeps a Buy rating on the shares after the company partnered with Duke-NUS to develop a coronavirus vaccine using its self-transcribing and replicating RNA technology STARR. Li tells investors in a research note that if successful, a 10-gram GMP batch could vaccinate over a 1 million population, adding that if validated in clinic, STARR mRNA vaccines could have significant manufacturing, cost and logistics advantages for vaccinating mass populations. The analyst thinks Arcturus' vaccine franchise has been overlooked, but now the potential for fast development of LUNAR-COV19 and its potential significant advantages over traditional vaccine could help unlock its value.